Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.
Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year.
FY2025 Management Guidance at CER reflects residual carry-over of VYVANSE® generic impact, continued efficiency savings and investment in R&D and launch preparation for Takeda’s late-stage pipeline.
Takeda chief executive officer, Christophe Weber, commented:
“Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Launch Products portfolio and the ability of our multi-year efficiency program to deliver meaningful cost savings.
“FY2025 will be a pivotal year as we invest in launch readiness for the late-stage pipeline, which will contribute to our broadly flat Core Operating Profit outlook for FY2025 but will be key to achieving Takeda’s long-term growth potential.”
Takeda chief financial officer, Milano Furuta, commented:
“Takeda's success in delivering revenue and Core Operating Profit growth in FY2024 and our outlook for broadly flat revenue and profit in FY2025, demonstrates our ability to manage through one of the largest generic impacts on our business in Takeda’s history while progressing a highly promising late-stage pipeline. Our performance and outlook speak to the strength of our Growth & Launch Products, our innovative pipeline and the resilience of our organization as a whole.
“Takeda is now at an inflection point, with multiple anticipated Phase 3 data readouts this fiscal year, and I’m excited about our growth trajectory.”
FINANCIAL HIGHLIGHTS for FY2024 Ended March 31, 2025 | |||
(Billion yen, except percentages and per share amounts) | |||
FY2024 | FY2023 | vs. PRIOR YEAR (Actual % change) | |
Revenue | 4,581.6 | 4,263.8 | +7.5% |
Operating Profit | 342.6 | 214.1 | +60.0% |
Net Profit | 107.9 | 144.1 | -25.1% |
EPS (Yen) | 68 | 92 | -25.8% |
Operating Cash Flow | 1,057.2 | 716.3 | +47.6% |
Adjusted Free Cash Flow (Non-IFRS) | 769.0 | 283.4 | +171.3% |
Core (Non-IFRS) | ||||
(Billion yen, except percentages and per share amounts) | ||||
FY2024 | FY2023 | vs. PRIOR YEAR (Actual % change) | vs. PRIOR YEAR (CER % change) | |
Revenue | 4,579.8 | 4,263.8 | +7.4% | +2.8% |
Operating Profit | 1,162.6 | 1,054.9 | +10.2% | +4.9% |
Margin | 25.4% | 24.7% | +0.6pp | ― |
Net Profit | 775.6 | 756.8 | +2.5% | -3.4% |
EPS (Yen) | 491 | 484 | +1.5% | -4.3% |
FY2025 Outlook | ||
(Billion yen, except percentages and per share amounts) | ||
Item | FY2025 FORECAST | FY2025 MANAGEMENT GUIDANCE Core Change at CER (Non-IFRS) |
Revenue | 4,530.0 | --- |
Core Revenue (Non-IFRS) | 4,530.0 | Broadly flat |
Operating Profit | 475.0 | --- |
Core Operating Profit (Non-IFRS) | 1,140.0 | Broadly flat |
Net Profit | 228.0 | --- |
EPS (Yen) | 145 | --- |
Core EPS (Yen) (Non-IFRS) | 485 | Broadly flat |
Adjusted Free Cash Flow (Non-IFRS) | 750.0-850.0 | --- |
Annual Dividend per Share (Yen) | 200 | --- |
Additional Information About Takeda’s FY2024 Results
For more details about Takeda’s FY2024 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda’s FY2024 Q4 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/)
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Financial information and Non-IFRS Measures
Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).
This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2024 investor presentation (available at www.takeda.com/investors). Beginning in the quarter ended June 30, 2024, Takeda (i) changed its methodology for CER adjustments to results of subsidiaries in hyperinflation countries to present those results in a manner consistent with IAS 29, Financial Reporting in Hyperinflation Economies, (ii) re-named Free Cash Flow as previously calculated as “Adjusted Free Cash Flow” (with “Free Cash Flow” to be reported as Operating Cash Flow less Property, Plant and Equipment), and (iii) re-named Net Debt as previously calculated as “Adjusted Net Debt” (with “Net Debt” to be reported as the book value of bonds and loans less cash and cash equivalents).
Medical information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Please refer to slide 5 of Takeda’s FY2024 Q4 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/) for the definition of Growth & Launch Products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250427084429/en/
Contacts
Investor Relations
Christopher O’Reilly
Christopher.oreilly@takeda.com - christopher.oreilly@takeda.com
+81 (0) 90-6481-3412
Media Relations
Brendan Jennings
Brendan.jennings@takeda.com
+81 (0) 80-2705-8259
(Outside Japan business hours)
Media_relations@takeda.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
G42 Launches OpenAI GPT-OSS Globally on Core42's AI Cloud13.8.2025 19:26:00 EEST | Press release
Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced the availability of OpenAI’s latest open-weight AI models, including gpt-oss-20B and gpt-oss-120B, on the Core42 AI Cloud platform, instantly accessible through the Core42 Compass API. The deployment enables enterprises, researchers, and developers to run the models on a choice of leading silicon platforms with sovereign, scalable, and high-performance capabilities. Integrated into Compass API with the flexibility to access a wide spectrum of high-performance compute platforms, Core42 delivers industry-leading inference speeds of up to 3,000 tokens per second per user, enabling real-time AI at global scale while aligning workloads with the optimal infrastructure for price-performance and scalability. This deployment delivers tailored performance for low-latency inference workloads and applications, reinforcing Core42’s commitment to secure and optimized global sovereign-enabled AI infrastructure. “Co
Cross-Platform Developers Get Full Control Over Game Distribution With New Features for Xsolla Publishing Suite13.8.2025 19:00:00 EEST | Press release
Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today a major expansion of its Publishing Suite, a one-stop modular solution built for PC, web, and cross-platform games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813620658/en/ (Graphic: Xsolla) As development and marketing costs continue to rise, developers and publishers are seeking new high-margin revenue streams that complement their existing strategies on Steam, Epic, and console. The Publishing Suite is uniquely positioned to help teams enable direct-to-consumer monetization regardless of a game's genre, size, and lifecycle stage. With full control over distribution, storefronts, and player engagement, studios can tailor the experience to any business model or use case. The latest updates to the Xsolla Publishing Suite further enhance its value for free-to-play (F2P) and buy-to-play (B2P) games, enabling faste
LambdaTest Unveils the Fourth Edition of the Testµ ('TestMu') Conference in 202513.8.2025 19:00:00 EEST | Press release
LambdaTest, a leading GenAI-native quality engineering platform, is excited to unveil the 4th edition of its flagship Testµ (‘TestMu’) Conference, taking place virtually from August 19–21, 2025. This year’s event is set to host over 50,000 quality, engineering, and DevOps professionals from more than 120 countries, making it one of the largest online global gatherings dedicated to the future of quality engineering. Testµ (‘TestMu’) Conference 2025 is designed to explore cutting-edge trends, emerging tools, and breakthrough innovations shaping the world of technology. With an esteemed lineup of 100+ global speakers, the conference will feature some of the most influential voices in tech, including Angie Jones, Global Vice President of Developer Relations of Block; Bratin Saha, Chief Product and Technology Officer of DigitalOcean; Dana Lawson, Chief Technology Officer of Netlify; Luis Héctor Chávez, Chief Technology Officer of Replit; Subba Ramaswamy, Managing Director of Accenture; and
Incentive and Recognition Insight on a Global Scale13.8.2025 18:20:00 EEST | Press release
The Incentive Marketing Association (IMA) undertook an extensive year-long global research project to deliver data that is designed to provide actionable incentive and recognition strategy for customer engagement and brand loyalty. The Incentive & Recognition Insights 2025 report synthesizes insights from over 600 executives worldwide, offering comprehensive global benchmarks and trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806639332/en/ IMA Global Market Report Cover “We hoped this study would provide a unified voice to represent the global industry," says Fintan Connolly, Consultant at Engage Loyalty, Research Chair, and past President of IMA Global. “We ran a comprehensive survey to get hard numbers and benchmarks, and we collected open-ended feedback and regional insights so we could capture the stories and context behind the numbers." As part of the global report, nine exclusive reports were developed, prov
Celebrating the Osaka-Kansai Expo 2025 “Top Chef in OSAKA 2025” Featuring Massimo Bottura13.8.2025 18:00:00 EEST | Press release
To commemorate the Osaka-Kansai Expo 2025, the Come to Osaka Campaign Executive Committee—led by Osaka Prefecture, Osaka City, and the Osaka Convention & Tourism Bureau—will present a special culinary event: Top Chef in OSAKA 2025, featuring world-renowned Chef Massimo Bottura. From September 9 to 14, 2025, Chef Bottura will offer exclusive lunch and dinner courses at Restaurant SAKURA, Hotel New Otani Osaka. Located on the 18th floor, the elegant French restaurant offers panoramic views of Osaka Castle and lush surroundings. Chef Bottura’s bespoke menu will showcase the rich agricultural and culinary heritage of Osaka, with most ingredients sourced locally. This initiative supports regional farmers, producers, and chefs, while promoting Osaka’s culinary excellence on a global stage. Massimo Bottura is the chef patron of Osteria Francescana, a three-Michelin-starred and Michelin Green Starred restaurant in Modena, Italy, and a two-time winner of The World’s 50 Best Restaurants. He is a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom